Pay-for-delay ruling exposes uncertainty in EU law

The Paroxetine judgment in the UK highlights a slew of questions that the EU courts have yet to resolve about patent settlements, and takes issue with the UK competition enforcer’s reasoning on market definitions. Tom Webb scrutinises the ruling


Get unlimited access to all Global Competition Review content